Bayer has notified the FDA that it will remove all remaining stocks of Trasylol (aprotinin injection) from the U.S. market due to the final results of the BART study which showed an increased risk of death with Trasylol compared with aminocaproic acid and tranexamic acid.

Access to Trasylol will be limited to investigational use based on a special treatment protocol. The protocol allows treatment for certain patients with an increased risk of blood loss and transfusions during coronary artery bypass graft (CABG) surgery and who have no acceptable alternative therapy. Physicians using Trasylol must verify that the drug benefits clearly outweigh the risks for their patients.

For more information call (888) 842-2937 or visit www.trasylol.com.